Clinical experience in coronary bypass surgery for abciximab-treated patients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 10966008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Abciximab effectively inhibits platelet aggregation and, therefore, there is considerable concern regarding bleeding complications in patients who require coronary artery bypass graft (CABG) surgery while affected by the drug. This presentation reviews the available published literature regarding CABG in abciximab-treated patients, the clinical results of emergency CABG in 12 patients, and management suggestions for the abciximab-treated patient requiring emergency surgery.
Medical subject headings
- Antibodies, Monoclonal
- Blood Loss, Surgical
- Coronary Artery Bypass
- Coronary Disease
- Immunoglobulin Fab Fragments
- Platelet Aggregation Inhibitors
- Postoperative Hemorrhage